Phase 1 study builds on early signals of anti-tumor activity in patients with refractory T and B cell lymphomas ...
Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrollingASPENOVA designed as confirmatory study to support DENALI Phase 2 accelerated approval ...
6d
Newleos Announces Dosing of First Participant in Phase 1b Study of NTX-2001 for Alcohol Use Disorder
Newleos doses the first participant in a Phase 1b study of NTX-2001, a potential first-in-class TAAR1 partial agonist for ...
CREATE Medicines, Inc., ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune cell programming, today ...
Anifrolumab-fnia, an IFNAR1-blocking monoclonal antibody, is now authorized for weekly subcutaneous self-administration in ...
LONDON & CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, has announced enrollment of the first two patients in the ...
China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. Wednesday, Chinese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results